Active Biotech AB Interim report January-March 2009

* Laquinimod -- Fast Track status granted by the FDA
* 57-57 -- planning of exploratory study in progress
* RhuDex(TM) -- preclinical tests under way
* ANYARA -- Phase III trial proceeding as planned
* TASQ -- safety profile assessed by independent international expert
  group, Phase II trial proceeding as planned
* Net sales SEK 2.2 M (3.2)
* Operating loss SEK 63.7 M (loss: 52.2)
* Loss after tax SEK 62.2 M (loss: 52.7)
* Loss per share for the period was SEK 1.21 (loss 1.11)

For further information, please contact:

  Tomas Leanderson
  President and CEO
  Tel: +46 (0)46-19 20 95

  Göran Forsberg
  VP Investor Relations & Business Development
  Tel: +46 (0)46-19 11 54

  Hans Kolam
  CFO
  Tel: +46 (0)46-19 20 44

  Active Biotech AB (Corp. Reg. No. 556223-9227)
  PO Box 724, 220 07 Lund
  Sweden
  Tel: +46 (0)46-19 20 00
  Fax: +46 (0)46-19 11 00

  This report is also available at www.activebiotech.com

Active Biotech AB Interim report January-March 2009

Attachments